Online tools will help physicians determine treatment strategies
NATICK, Mass. and BARCELONA, Spain, May 19 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today welcomed the launch of a new website, www.syntaxscore.com, dedicated to the understanding and use of the SYNTAX Score(TM), a novel angiographic tool used to measure the complexity of coronary artery disease. The Company made the announcement at the annual EuroPCR Scientific Program in Barcelona.
The SYNTAX Score was developed in connection with the SYNTAX trial, the first randomized, controlled clinical trial to compare percutaneous coronary intervention (PCI) using the TAXUS(R) Express2(R) Paclitaxel-Eluting Coronary Stent System to coronary artery bypass graft (CABG) surgery in patients with left main disease and/or significant narrowing of all three coronary arteries (three-vessel disease). These complex patients are traditionally treated with CABG and have been excluded from most prior drug-eluting stent clinical trials. The SYNTAX trial provides important data related to the treatment of these complex patients and should help physicians make more informed treatment decisions.
The SYNTAX Score was used in the trial to characterize coronary anatomy based on nine anatomic criteria, including lesion frequency, complexity and location; it assigned a score to each patient. Higher SYNTAX Scores indicate patients with more complex disease and increased treatment challenges.
The new website allows cardiologists and cardiac surgeons to calculate a patient's SYNTAX Score and create a description of anatomical complexity of the coronary vasculature that can be used in combination with a physician's broader clinical judgment to aid in determining the best revascularization option. The site also includes a detailed tutorial on the use of the SYNTAX Score calculator, including definitions and example cases, together with SYNTAX data presentations and publications.
"The SYNTAX Score website will be an important tool to assist with revascularization strategies in these complex patient populations," said Patrick W. Serruys, M.D., Ph.D., Chief of Interventional Cardiology, Thoraxcenter-
The SYNTAX trial will continue to provide important data throughout the life of the trial (one-, three- and five-year outcomes). As more data become available, awareness and understanding of the SYNTAX trial will increase as will the utility of the SYNTAX Score.
"Boston Scientific is pleased to contribute the SYNTAX trial data to the advancement of evidence-based medicine," said Keith D. Dawkins, M.D., Associate Chief Medical Officer of Boston Scientific. "The patients enrolled in SYNTAX have exceptionally complex anatomy and advanced disease, representing an unprecedented study group for a stent trial. Ongoing findings from this study will continue to be used to enhance the value of the SYNTAX Score in this high-risk patient population."
Boston Scientific will be announcing subset data analyses from the SYNTAX trial this week at EuroPCR.
The SYNTAX Score and SYNTAX Score website were developed under the direction of the SYNTAX trial steering committee, chaired by Dr. Serruys and F.W. Mohr, M.D., Ph.D., and were made possible by support from Boston Scientific and Cardialysis BV.
The safety and effectiveness of the TAXUS(R) Express2(R) Paclitaxel-Eluting Coronary Stent System has not been established in patients with left main or three-vessel disease. The SYNTAX Score and related materials are not intended to provide medical advice or guidance as to appropriate treatment strategies for individual patients.
Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: www.bostonscientific.com.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding clinical trials, regulatory approvals, competitive offerings and product performance. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.
Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A- Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file thereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.
CONTACT: Paul Donovan 508-650-8541 (office) 508-667-5165 (mobile) Media Relations Boston Scientific Corporation Natacha Gassenbach (onsite at PCR) 508-250-9348 (mobile) 33 1 6 08 97 70 36 (mobile) Media Relations Boston Scientific Corporation Larry Neumann 508-650-8696 (office) Investor Relations Boston Scientific Corporation
|SOURCE Boston Scientific Corporation|
Copyright©2009 PR Newswire.
All rights reserved